Symbols / BMRA $2.00 +1.52%
BMRA Chart
About
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 6.04M |
| Enterprise Value | 3.78M | Income | -4.03M | Sales | 4.46M |
| Book/sh | 1.50 | Cash/sh | 0.84 | Dividend Yield | — |
| Payout | 0.00% | Employees | 53 | IPO | — |
| P/E | — | Forward P/E | 5.13 | PEG | — |
| P/S | 1.36 | P/B | 1.33 | P/C | — |
| EV/EBITDA | -0.73 | EV/Sales | 0.85 | Quick Ratio | 2.18 |
| Current Ratio | 3.25 | Debt/Eq | 6.40 | LT Debt/Eq | — |
| EPS (ttm) | -2.51 | EPS next Y | 0.39 | EPS Growth | — |
| Revenue Growth | -26.00% | Earnings | 2023-04-14 16:00 | ROA | -49.44% |
| ROE | -84.30% | ROIC | — | Gross Margin | 5.63% |
| Oper. Margin | -113.47% | Profit Margin | -90.31% | Shs Outstand | 3.02M |
| Shs Float | 2.70M | Short Float | 2.28% | Short Ratio | 4.13 |
| Short Interest | — | 52W High | 5.92 | 52W Low | 1.87 |
| Beta | 0.23 | Avg Volume | 62.96K | Volume | 9.47K |
| Target Price | — | Recom | None | Prev Close | $1.97 |
| Price | $2.00 | Change | 1.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.00
Latest analyst target
3. DCF / Fair value
$-10.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2020-10-19 | main | Aegis Capital | — → Buy | $11 |
| 2020-09-04 | main | Aegis Capital | — → Buy | $13 |
| 2020-08-21 | init | Aegis Capital | — → Buy | $10 |
| 2018-12-17 | main | B. Riley Securities | Buy → Buy | $6 |
- New finger-stick IBS test eases pain and bloating for most patients - Stock Titan hu, 26 Feb 2026 08
- Why BMRA stock attracts global investors - Portfolio Gains Summary & Stepwise Trade Execution Plans - mfd.ru Sun, 15 Mar 2026 02
- Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain - The Globe and Mail hu, 05 Mar 2026 08
- symbol__ Stock Quote Price and Forecast - CNN Sun, 31 Mar 2024 09
- Medicare sets $300 price for new food-trigger test to ease IBS pain - Stock Titan ue, 23 Dec 2025 08
- Biomerica, Inc. Announces 1-for-8 Reverse Stock Split Effective April 21, 2025 - Nasdaq Wed, 16 Apr 2025 07
- Biomerica (BMRA) Expands Market with UK Approval for hp+detect T - GuruFocus hu, 05 Mar 2026 14
- Biomerica’s Market Presence Expands with Egyptian Drug Authority Authorization - timothysykes.com ue, 23 Dec 2025 08
- Biomerica, Inc. Reports Successful Responder Analysis Results for inFoods® IBS and Establishes $300 Medicare Payment Rate - Quiver Quantitative hu, 26 Feb 2026 08
- January 2025 US Penny Stocks With Promising Potential - Yahoo Finance Fri, 17 Jan 2025 08
- Biomerica, Inc. Reports 4% Decline in Operating Expenses Year-to-Date and Strengthens Balance Sheet with 14.7% Improvement in Working Capital - Quiver Quantitative Wed, 14 Jan 2026 08
- BMRA - Biomerica Inc Latest Stock News & Market Updates - Stock Titan ue, 08 Sep 2020 13
- Biomerica Receives Approval for EZ Detect™ Colorectal Disease Test in Vietnam, Expanding Access to At-Home Cancer Screening - Quiver Quantitative Wed, 18 Feb 2026 08
- Biomerica, Inc. Reports 5% Year-Over-Year Revenue Growth and Improved Financial Performance in Q2 Fiscal 2025 - Quiver Quantitative Wed, 15 Jan 2025 08
- Biomerica granted extension to regain Nasdaq compliance - Investing.com hu, 07 Nov 2024 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 52500 | — | — | Stock Award(Grant) at price 0.00 per share. | IRANI ZACKARY S | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
| 1 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | BARBIERI ALLEN | Officer and Director | — | 2025-12-12 00:00:00 | D |
| 2 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | MOATAZEDI DAVID | Director | — | 2025-12-12 00:00:00 | D |
| 3 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | HUFF GARY M | Director | — | 2025-12-12 00:00:00 | D |
| 4 | 22500 | — | — | Stock Award(Grant) at price 0.00 per share. | CHIN ERIC | Director | — | 2025-12-12 00:00:00 | D |
| 5 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | LU GARY | Chief Financial Officer | — | 2025-12-12 00:00:00 | D |
| 6 | 250000 | 77500 | — | Stock Award(Grant) at price 0.31 per share. | IRANI ZACKARY S | Chief Executive Officer | — | 2024-12-13 00:00:00 | D |
| 7 | 110000 | 34100 | — | Stock Award(Grant) at price 0.31 per share. | BARBIERI ALLEN | Officer and Director | — | 2024-12-13 00:00:00 | D |
| 8 | 85000 | 26350 | — | Stock Award(Grant) at price 0.31 per share. | EMERSON JANE | Director | — | 2024-12-13 00:00:00 | D |
| 9 | 85000 | 26350 | — | Stock Award(Grant) at price 0.31 per share. | MOATAZEDI DAVID | Director | — | 2024-12-13 00:00:00 | D |
Financials
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -4.74M | -5.99M | -6.87M | -3.94M |
| TotalUnusualItems | 66.86K | |||
| TotalUnusualItemsExcludingGoodwill | 66.86K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.97M | -5.98M | -7.14M | -4.53M |
| ReconciledDepreciation | 400.00K | 374.00K | 351.00K | 595.00K |
| ReconciledCostOfRevenue | 4.81M | 4.80M | 4.89M | 15.89M |
| EBITDA | -4.74M | -5.99M | -6.87M | -3.94M |
| EBIT | -5.14M | -6.37M | -7.22M | -4.53M |
| NetInterestIncome | 165.00K | 431.00K | 133.00K | 27.00K |
| InterestExpense | 0.00 | 367.00 | ||
| InterestIncome | 165.00K | 431.00K | 133.00K | 27.00K |
| NormalizedIncome | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.97M | -5.98M | -7.14M | -4.53M |
| TotalExpenses | 10.45M | 11.78M | 12.56M | 23.41M |
| TotalOperatingIncomeAsReported | -5.14M | -6.37M | -7.22M | -4.53M |
| DilutedAverageShares | 2.30M | 2.10M | 1.77M | 1.58M |
| BasicAverageShares | 2.30M | 2.10M | 1.77M | 1.58M |
| DilutedEPS | -2.16 | -2.84 | -4.00 | -2.88 |
| BasicEPS | -2.16 | -2.84 | -4.00 | -2.88 |
| DilutedNIAvailtoComStockholders | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeCommonStockholders | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncome | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeIncludingNoncontrollingInterests | -4.97M | -5.98M | -7.14M | -4.53M |
| NetIncomeContinuousOperations | -4.97M | -5.98M | -7.14M | -4.53M |
| TaxProvision | 1.00K | 42.00K | 51.00K | 24.00K |
| PretaxIncome | -4.97M | -5.94M | -7.09M | -4.51M |
| OtherIncomeExpense | 1.00K | 66.86K | ||
| OtherNonOperatingIncomeExpenses | 1.00K | |||
| GainOnSaleOfSecurity | 66.86K | |||
| NetNonOperatingInterestIncomeExpense | 165.00K | 431.00K | 133.00K | 27.00K |
| InterestExpenseNonOperating | 0.00 | 367.00 | ||
| InterestIncomeNonOperating | 165.00K | 431.00K | 133.00K | 27.00K |
| OperatingIncome | -5.14M | -6.37M | -7.22M | -4.53M |
| OperatingExpense | 5.63M | 6.98M | 7.67M | 7.51M |
| ResearchAndDevelopment | 1.02M | 1.49M | 1.58M | 1.81M |
| SellingGeneralAndAdministration | 4.61M | 5.49M | 6.08M | 5.70M |
| GrossProfit | 498.00K | 611.00K | 446.00K | 2.98M |
| CostOfRevenue | 4.81M | 4.80M | 4.89M | 15.89M |
| TotalRevenue | 5.31M | 5.42M | 5.34M | 18.87M |
| OperatingRevenue | 5.31M | 5.42M | 5.34M | 18.87M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.55M | 2.10M | 2.10M | 1.61M |
| ShareIssued | 2.55M | 2.10M | 2.10M | 1.61M |
| TotalDebt | 458.00K | 785.00K | 1.08M | 1.38M |
| TangibleBookValue | 3.88M | 6.38M | 11.56M | 8.15M |
| InvestedCapital | 4.11M | 6.59M | 11.72M | 8.32M |
| WorkingCapital | 3.13M | 5.53M | 10.85M | 7.42M |
| NetTangibleAssets | 3.88M | 6.38M | 11.56M | 8.15M |
| CapitalLeaseObligations | 458.00K | 785.00K | 1.08M | 1.38M |
| CommonStockEquity | 4.11M | 6.59M | 11.72M | 8.32M |
| TotalCapitalization | 4.11M | 6.59M | 11.72M | 8.32M |
| TotalEquityGrossMinorityInterest | 4.11M | 6.59M | 11.72M | 8.32M |
| StockholdersEquity | 4.11M | 6.59M | 11.72M | 8.32M |
| GainsLossesNotAffectingRetainedEarnings | -105.00K | -102.00K | -110.00K | -74.00K |
| OtherEquityAdjustments | -105.00K | -102.00K | -110.00K | -74.00K |
| RetainedEarnings | -53.17M | -48.20M | -42.22M | -35.08M |
| AdditionalPaidInCapital | 57.17M | 54.72M | 52.70M | 42.45M |
| CapitalStock | 203.00K | 168.00K | 1.35M | 1.03M |
| CommonStock | 203.00K | 168.00K | 1.35M | 1.03M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.84M | 2.66M | 2.73M | 3.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 100.00K | 459.00K | 785.00K | 1.04M |
| LongTermDebtAndCapitalLeaseObligation | 100.00K | 459.00K | 785.00K | 1.04M |
| LongTermCapitalLeaseObligation | 100.00K | 459.00K | 785.00K | 1.04M |
| CurrentLiabilities | 1.74M | 2.20M | 1.95M | 2.01M |
| OtherCurrentLiabilities | 372.00 | 380.00 | ||
| CurrentDeferredLiabilities | 55.00K | 85.00K | 60.00K | 51.00K |
| CurrentDeferredRevenue | 55.00K | 85.00K | 60.00K | 51.00K |
| CurrentDebtAndCapitalLeaseObligation | 358.00K | 326.00K | 297.00K | 341.00K |
| CurrentCapitalLeaseObligation | 358.00K | 326.00K | 297.00K | 341.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 655.00K | 655.00K | 696.00K | 647.00K |
| PayablesAndAccruedExpenses | 672.00K | 1.14M | 892.00K | 972.00K |
| CurrentAccruedExpenses | 377.00K | 578.00K | 548.00K | 236.00K |
| Payables | 295.00K | 560.00K | 344.00K | 736.00K |
| AccountsPayable | 295.00K | 560.00K | 344.00K | 736.00K |
| TotalAssets | 5.95M | 9.25M | 14.45M | 11.37M |
| TotalNonCurrentAssets | 1.07M | 1.52M | 1.66M | 1.95M |
| OtherNonCurrentAssets | 113.00K | 203.00K | 79.00K | 96.00K |
| InvestmentsAndAdvances | 165.00K | 165.00K | 165.00K | 165.00K |
| InvestmentinFinancialAssets | 165.00K | 165.00K | 165.00K | 165.00K |
| GoodwillAndOtherIntangibleAssets | 228.00K | 212.00K | 165.00K | 170.00K |
| OtherIntangibleAssets | 228.00K | 212.00K | 165.00K | 170.00K |
| NetPPE | 564.00K | 943.00K | 1.25M | 1.52M |
| AccumulatedDepreciation | -2.68M | -2.30M | -1.95M | -2.03M |
| GrossPPE | 3.25M | 3.25M | 3.20M | 3.55M |
| OtherProperties | 3.04M | 3.04M | 2.98M | 3.32M |
| MachineryFurnitureEquipment | 211.00K | 211.00K | 211.00K | 227.00K |
| CurrentAssets | 4.88M | 7.73M | 12.80M | 9.43M |
| OtherCurrentAssets | 255.00K | 238.00K | 300.00K | 320.00K |
| PrepaidAssets | 238.00K | 300.00K | 320.28K | 370.29K |
| Inventory | 1.49M | 2.38M | 2.06M | 2.42M |
| InventoriesAdjustmentsAllowances | -471.00K | -467.00K | -672.00K | -846.00K |
| FinishedGoods | 147.00K | 179.00K | 182.00K | 782.00K |
| WorkInProcess | 743.00K | 1.15M | 869.00K | 763.00K |
| RawMaterials | 1.07M | 1.52M | 1.68M | 1.72M |
| Receivables | 731.00K | 947.00K | 722.00K | 774.00K |
| AccountsReceivable | 731.00K | 947.00K | 722.00K | 774.00K |
| AllowanceForDoubtfulAccountsReceivable | -26.00K | -19.00K | -29.00K | -153.00K |
| GrossAccountsReceivable | 757.00K | 966.00K | 751.00K | 927.00K |
| CashCashEquivalentsAndShortTermInvestments | 2.40M | 4.17M | 9.72M | 5.92M |
| CashAndCashEquivalents | 2.40M | 4.17M | 9.72M | 5.92M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.88M | -5.48M | -5.55M | -649.00K |
| RepurchaseOfCapitalStock | 0.00 | -705.00K | -85.00K | -165.92K |
| IssuanceOfCapitalStock | 2.14M | 0.00 | 10.01M | 2.40M |
| CapitalExpenditure | -37.00K | -115.00K | -78.00K | -170.00K |
| InterestPaidSupplementalData | 367.00 | |||
| IncomeTaxPaidSupplementalData | 10.00K | 41.00K | 51.00K | 24.00K |
| EndCashPosition | 2.40M | 4.17M | 9.72M | 5.92M |
| BeginningCashPosition | 4.17M | 9.72M | 5.92M | 4.20M |
| EffectOfExchangeRateChanges | -3.00K | 8.00K | -36.00K | -26.00K |
| ChangesInCash | -1.77M | -5.56M | 3.84M | 1.74M |
| FinancingCashFlow | 2.11M | -81.00K | 9.39M | 2.39M |
| CashFlowFromContinuingFinancingActivities | 2.11M | -81.00K | 9.39M | 2.39M |
| NetOtherFinancingCharges | -47.00K | -81.00K | -705.00K | -85.00K |
| ProceedsFromStockOptionExercised | 15.00K | 0.00 | 81.00K | 77.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 2.14M | 0.00 | 10.01M | 2.40M |
| CommonStockPayments | 0.00 | -705.00K | -85.00K | -165.92K |
| CommonStockIssuance | 2.14M | 0.00 | 10.01M | 2.40M |
| InvestingCashFlow | -37.00K | -115.00K | -78.00K | -170.00K |
| CashFlowFromContinuingInvestingActivities | -37.00K | -115.00K | -78.00K | -170.00K |
| NetIntangiblesPurchaseAndSale | -14.00K | -113.00K | -159.73K | |
| PurchaseOfIntangibles | -14.00K | -113.00K | -159.73K | |
| NetPPEPurchaseAndSale | 0.00 | -51.00K | -64.00K | -57.00K |
| PurchaseOfPPE | 0.00 | -51.00K | -64.00K | -57.00K |
| CapitalExpenditureReported | -37.00K | -64.00K | -14.00K | |
| OperatingCashFlow | -3.84M | -5.36M | -5.47M | -479.00K |
| CashFlowFromContinuingOperatingActivities | -3.84M | -5.36M | -5.47M | -479.00K |
| ChangeInWorkingCapital | 268.00K | -389.00K | 304.00K | 3.60M |
| ChangeInOtherWorkingCapital | -22.00K | 15.00K | 351.00K | 51.00K |
| ChangeInOtherCurrentLiabilities | -327.00K | -297.00K | -297.00K | -244.00K |
| ChangeInOtherCurrentAssets | 8.00K | -44.00K | 18.00K | 169.00K |
| ChangeInPayablesAndAccruedExpense | -465.00K | 205.00K | -31.00K | 647.00K |
| ChangeInAccruedExpense | 1.00K | -41.00K | 49.00K | 258.00K |
| ChangeInPayable | -466.00K | 246.00K | -80.00K | 389.00K |
| ChangeInAccountPayable | -466.00K | 246.00K | -80.00K | 389.00K |
| ChangeInPrepaidAssets | -17.00K | 62.00K | 20.00K | 50.00K |
| ChangeInInventory | 882.00K | -115.00K | 534.00K | 1.56M |
| ChangeInReceivables | 209.00K | -215.00K | -291.00K | 1.36M |
| ChangesInAccountReceivables | 209.00K | -215.00K | -291.00K | 1.36M |
| StockBasedCompensation | 460.00K | 837.00K | 1.19M | 1.26M |
| ProvisionandWriteOffofAssets | 4.00K | -205.00K | -174.00K | -1.46M |
| DepreciationAmortizationDepletion | 400.00K | 374.00K | 351.00K | 595.00K |
| DepreciationAndAmortization | 400.00K | 374.00K | 351.00K | 595.00K |
| Depreciation | 400.00K | 374.00K | 351.00K | 595.00K |
| OperatingGainsLosses | 53.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 53.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -4.97M | -5.98M | -7.14M | -4.53M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BMRA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|